TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Telomir Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.04−0.01 (-0.95%)
Close on Oct 19, 2026
- Market cap
- $63.27M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.53 (−33.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $63.27M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 12.57
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$5.88M
- EPS, diluted
- -$0.91
- Book value per share
- $0.08
- Diluted shares
- 61M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Net income
-$5.88M
EPS, diluted
-$0.91
Reported periodTrailing twelve months